Equities
  • Price (EUR)3.39
  • Today's Change-0.01 / -0.29%
  • Shares traded624.00
  • 1 Year change+8.67%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.

  • Revenue in EUR (TTM)463.85m
  • Net income in EUR94.75m
  • Incorporated--
  • Employees1.75k
  • Location
    Faes Farma SAEdificio 2, 2 IzquierdaMADRID 28033SpainESP
  • Phone+34 914680800
  • Fax+34 944818201
  • Websitehttps://faesfarma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.